Tags

Type your tag names separated by a space and hit enter

Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children.

Abstract

OBJECTIVE

Preclinical investigations support the use of probiotics in the treatment of hypercholesterolemia, but clinical evidence is often contrasting. The aim of this study was to evaluate the effects of a probiotic formulation containing three Bifidobacterium strains on lipid profiles in children affected by primary dyslipidemia.

METHODS

Thirty-eight children with dyslipidemia, ages 10.8 ± 2.1 y, were enrolled in a randomized, double-blind, placebo-controlled cross-over study. After a 4-wk diet run-in period, the children received probiotics (B. animalis subspecies lactis MB 2409, B. bifidum MB 109B, and B. longum subspecies longum BL04) or placebo for 3 mo. After 1 mo, wash-out treatments were switched. A strict dietary evaluation concerning satured fatty acids and cholesterol content, STEP I diet accordingly, was performed by a dietitian who examined the weekly dietary diary at each visit.

RESULTS

Baseline lipid profile was (mean ± SD): total cholesterol (TC) 222.8 ± 23.2 mg/dL, high-density lipoprotein cholesterol (HDL-C) 55.8 ± 12.2 mg/dL, triglycerides (TG) 99.0 ± 61.7 mg/dL, and low-density lipoprotein cholesterol (LDL-C) 147.2 ± 21.9 mg/dL. After 3 mo of probiotic treatment, the lipid profile was: TC 211.9 ± 27.3 mg/dL, HDL-C 60.7 ± 14.2 mg/dL, TG 79.5 ± 34.5 mg/dL, and LDL-C 135.3 ± 24.2 mg/dL. Compared with placebo, probiotics reduced TC by 3.4% (P = 0.02) and LDL-C by 3.8% (P = 0.001). No significant dietary change occurred through the study and no relevant adverse effects were observed.

CONCLUSIONS

Treatment with a Bifidobacterium probiotic formulation was well tolerated and useful in combination with to diet therapy. Children with dyslipidemia benefited from this approach, although the results need to be confirmed by larger controlled studies.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Dipartimento di Scienze della Sanità pubblica e Pediatriche, Università di Torino, Torino, Italy. Electronic address: ornella.guardamagna@unito.it.

    ,

    Dipartimento di Scienze della Vita, Università di Modena e Reggio Emilia, Modena, Italy.

    ,

    Dipartimento di Scienze Cardiovascolari, Università la Sapienza di Roma, Roma, Italy.

    ,

    Dipartimento di Scienze della Vita, Università di Modena e Reggio Emilia, Modena, Italy.

    ,

    Dipartimento di Scienze della Sanità pubblica e Pediatriche, Università di Torino, Torino, Italy.

    ,

    Dipartimento di Scienze della Sanità pubblica e Pediatriche, Università di Torino, Torino, Italy.

    Dipartimento di Scienze della Vita, Università di Modena e Reggio Emilia, Modena, Italy.

    Source

    MeSH

    Anticholesteremic Agents
    Bifidobacterium
    Child
    Cholesterol
    Cholesterol, HDL
    Cholesterol, LDL
    Cross-Over Studies
    Double-Blind Method
    Dyslipidemias
    Female
    Humans
    Hypercholesterolemia
    Male
    Probiotics
    Species Specificity
    Triglycerides

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    24985000

    Citation

    Guardamagna, Ornella, et al. "Bifidobacteria Supplementation: Effects On Plasma Lipid Profiles in Dyslipidemic Children." Nutrition (Burbank, Los Angeles County, Calif.), vol. 30, no. 7-8, 2014, pp. 831-6.
    Guardamagna O, Amaretti A, Puddu PE, et al. Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children. Nutrition. 2014;30(7-8):831-6.
    Guardamagna, O., Amaretti, A., Puddu, P. E., Raimondi, S., Abello, F., Cagliero, P., & Rossi, M. (2014). Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children. Nutrition (Burbank, Los Angeles County, Calif.), 30(7-8), pp. 831-6. doi:10.1016/j.nut.2014.01.014.
    Guardamagna O, et al. Bifidobacteria Supplementation: Effects On Plasma Lipid Profiles in Dyslipidemic Children. Nutrition. 2014;30(7-8):831-6. PubMed PMID: 24985000.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children. AU - Guardamagna,Ornella, AU - Amaretti,Alberto, AU - Puddu,Paolo Emilio, AU - Raimondi,Stefano, AU - Abello,Francesca, AU - Cagliero,Paola, AU - Rossi,Maddalena, Y1 - 2014/02/15/ PY - 2013/11/22/received PY - 2013/12/28/revised PY - 2014/01/16/accepted PY - 2014/7/3/entrez PY - 2014/7/6/pubmed PY - 2015/2/11/medline KW - Bifidobacterium KW - Child KW - Dyslipidemia KW - Hypercholesterolemia KW - Probiotics SP - 831 EP - 6 JF - Nutrition (Burbank, Los Angeles County, Calif.) JO - Nutrition VL - 30 IS - 7-8 N2 - OBJECTIVE: Preclinical investigations support the use of probiotics in the treatment of hypercholesterolemia, but clinical evidence is often contrasting. The aim of this study was to evaluate the effects of a probiotic formulation containing three Bifidobacterium strains on lipid profiles in children affected by primary dyslipidemia. METHODS: Thirty-eight children with dyslipidemia, ages 10.8 ± 2.1 y, were enrolled in a randomized, double-blind, placebo-controlled cross-over study. After a 4-wk diet run-in period, the children received probiotics (B. animalis subspecies lactis MB 2409, B. bifidum MB 109B, and B. longum subspecies longum BL04) or placebo for 3 mo. After 1 mo, wash-out treatments were switched. A strict dietary evaluation concerning satured fatty acids and cholesterol content, STEP I diet accordingly, was performed by a dietitian who examined the weekly dietary diary at each visit. RESULTS: Baseline lipid profile was (mean ± SD): total cholesterol (TC) 222.8 ± 23.2 mg/dL, high-density lipoprotein cholesterol (HDL-C) 55.8 ± 12.2 mg/dL, triglycerides (TG) 99.0 ± 61.7 mg/dL, and low-density lipoprotein cholesterol (LDL-C) 147.2 ± 21.9 mg/dL. After 3 mo of probiotic treatment, the lipid profile was: TC 211.9 ± 27.3 mg/dL, HDL-C 60.7 ± 14.2 mg/dL, TG 79.5 ± 34.5 mg/dL, and LDL-C 135.3 ± 24.2 mg/dL. Compared with placebo, probiotics reduced TC by 3.4% (P = 0.02) and LDL-C by 3.8% (P = 0.001). No significant dietary change occurred through the study and no relevant adverse effects were observed. CONCLUSIONS: Treatment with a Bifidobacterium probiotic formulation was well tolerated and useful in combination with to diet therapy. Children with dyslipidemia benefited from this approach, although the results need to be confirmed by larger controlled studies. SN - 1873-1244 UR - https://www.unboundmedicine.com/medline/citation/24985000/Bifidobacteria_supplementation:_effects_on_plasma_lipid_profiles_in_dyslipidemic_children_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0899-9007(14)00080-X DB - PRIME DP - Unbound Medicine ER -